RxDoctor Payments Data

Hailiu Zuo, MD

Internal Medicine · Elmhurst, NYNPI 1780771592

Payments from drug & device makers

$675in general payments, 2019–2025

Across 41 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$554
  • AbbVie$36
  • Pfizer$30
  • Amgen$25
  • Merck$16
  • GSK$14

What the payments were for

  • Food & beverage$63494%
  • Education$416%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amarin Pharma, Inc.34$554
AbbVie2$36
Pfizer2$30
Amgen1$25
Merck1$16
GSK1$14

How this compares

$675 in reported general payments places this provider in the 65th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$42,946
Medicare patients
83
Services billed
551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl1,564$809,384
Diclofenac Epolamine506$256,728
RestasisCyclosporine200$126,151
VemlidyTenofovir Alafenamide58$82,167
XareltoRivaroxaban100$76,474
JardianceEmpagliflozin61$57,983
EliquisApixaban58$57,602
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate64$53,659
NexiumEsomeprazole Magnesium125$40,758
JanuviaSitagliptin Phosphate38$35,669
CreonLipase/Protease/Amylase36$35,316
Lactulose15$31,628
FarxigaDapagliflozin Propanediol37$29,792
EntrestoSacubitril/Valsartan21$29,265
Fluocinonide467$27,904

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Creon, Linzess, Restasis Multidose$36$204,246304 claims
PfizerEliquis$30$57,60258 claims
MerckJanuvia, Janumet$16$55,81262 claims
GSKTrelegy Ellipta$14$6,84612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Elmhurst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →